Stoke Therapeutics to Present on First Precision Treatments for Genetic Epilepsies at J.P. Morgan Healthcare Conference
BEDFORD, Mass.--(BUSINESS WIRE)--Jan 3, 2019--Stoke Therapeutics will present on its pioneering work to develop the first gene-specific, disease-modifying therapies for genetic epilepsies at the 37 th Annual J.P. Morgan Healthcare Conference in San Francisco next week.
Chief Executive Officer Ed Kaye, M.D., will share details on Stoke’s novel approach to upregulate gene expression with antisense oligonucleotide therapies. The technology, Targeted Augmentation of Nuclear Gene Output (TANGO), is designed to restore protein production to normal levels in patients with autosomal dominant disorders in which one copy of a gene is healthy and the other is dysfunctional.
Stoke’s lead indication is Dravet Syndrome, a rare and devastating form of genetic epilepsy that affects more than 35,000 patients in the U.S., the European Union and Japan. Dr. Kaye will present data showing that Stoke’s TANGO technology successfully increases production of the key protein missing in Dravet Syndrome, Na v 1.1, in a highly precise, durable and controlled manner in mouse models. Stoke’s drug candidate would be the first therapy to address the root cause of Dravet Syndrome and modify the course of the disease.
Stoke is also advancing programs using TANGO in other disorders of the central nervous system as well as genetic diseases of the eye, liver and kidney.
Stoke’s presentation details:
Date: Tuesday, January 8, 2019 Time: 10 – 10:25 a.m. PST Location: Westin St. Francis Hotel, Elizabethan Room D
About Stoke Therapeutics Launched in 2018, Stoke Therapeutics is a biotechnology company working to increase gene expression to treat a wide array of severe genetic diseases, including genetic conditions affecting the central nervous system, eye, liver and kidney. Stoke has raised $130 million in funding from two rounds of financing; investors include Apple Tree Partners, RTW Investments, RA Capital Management, Cormorant Asset Management, Perceptive Advisors, funds managed by Janus Henderson Investors, Redmile Group, Sphera Funds Management, and Alexandria Venture Investments. For more information, visit www.StokeTherapeutics.com and follow Stoke on Twitter @StokeTx.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190103005119/en/
CONTACT: Sara Green
Ten Bridge Communications
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA MASSACHUSETTS
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY GENETICS PHARMACEUTICAL
SOURCE: Stoke Therapeutics
Copyright Business Wire 2019.
PUB: 01/03/2019 07:00 AM/DISC: 01/03/2019 07:01 AM